| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5206244 | BRISTOL MYERS SQUIBB | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
Feb, 2015
(9 years ago) | |
|
US5206244 (Pediatric) | BRISTOL MYERS SQUIBB | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
Aug, 2015
(8 years ago) | |
Baraclude is owned by Bristol Myers Squibb.
Baraclude contains Entecavir.
Baraclude has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Baraclude are:
- US5206244
- US5206244*PED
Baraclude was authorised for market use on 29 March, 2005.
Baraclude is available in tablet;oral, solution;oral dosage forms.
The generics of Baraclude are possible to be released after 20 September, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Sep 20, 2017 |
| New Dosing Schedule(D-127) | Oct 15, 2013 |
| New Patient Population(NPP) | Oct 12, 2015 |
Drugs and Companies using ENTECAVIR ingredient
Market Authorisation Date: 29 March, 2005
Treatment: NA
Dosage: TABLET;ORAL; SOLUTION;ORAL
How can I launch a generic of BARACLUDE before it's drug patent expiration?
More Information on Dosage
BARACLUDE family patents
